Seems like_老虎社区_美港股上老虎

IcySilver
2021-12-24

Seems like selling well established asset that are not making enough profit margin.

Reckitt to sell E45 skincare brand to Karo Pharma for $268 million

-Reckitt Benckiser said on Friday it plans to sell its E45 skincare brand and related sub-brands to Karo Pharma for 200 million pounds , as the British consumer goods maker shifts focus to higher growth areas.The Durex condom and Lysol disinfectant maker said the businesses generated a combined net revenue of 43 million pounds last year.The Slough-based company has been trimming its portfolio to concentrate on high growth categories such as disinfectants and health care products that have seen

Reckitt to sell E45 skincare brand to Karo Pharma for $268 million

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":698881206,"tweetId":"698881206","gmtCreate":1640339678235,"gmtModify":1640341230696,"author":{"id":3574577404599862,"authorId":3574577404599862,"authorIdStr":"3574577404599862","name":"IcySilver","avatar":"https://static.tigerbbs.com/484d3b69652c2ca3d6cd65bc1007a60b","vip":2,"userType":2,"introduction":"Price action trader, student of the market","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Seems like selling well established asset that are not making enough profit margin.</p></body></html>","htmlText":"<html><head></head><body><p>Seems like selling well established asset that are not making enough profit margin.</p></body></html>","text":"Seems like selling well established asset that are not making enough profit margin.","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698881206","repostId":1166205101,"repostType":4,"repost":{"id":"1166205101","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640335600,"share":"https://www.laohu8.com/m/news/1166205101?lang=&edition=full","pubTime":"2021-12-24 16:46","market":"us","language":"en","title":"Reckitt to sell E45 skincare brand to Karo Pharma for $268 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1166205101","media":"Reuters","summary":" -Reckitt Benckiser said on Friday it plans to sell its E45 skincare brand and related sub-brands to Karo Pharma for 200 million pounds , as the British consumer goods maker shifts focus to higher growth areas.The Durex condom and Lysol disinfectant maker said the businesses generated a combined net revenue of 43 million pounds last year.The Slough-based company has been trimming its portfolio to concentrate on high growth categories such as disinfectants and health care products that have seen ","content":"<p>(Reuters) -Reckitt Benckiser said on Friday it plans to sell its E45 skincare brand and related sub-brands to Karo Pharma for 200 million pounds ($267.98 million), as the British consumer goods maker shifts focus to higher growth areas.</p>\n<p>The Durex condom and Lysol disinfectant maker said the businesses generated a combined net revenue of 43 million pounds last year.</p>\n<p>The Slough-based company has been trimming its portfolio to concentrate on high growth categories such as disinfectants and health care products that have seen a boom during the COVID-19 pandemic.</p>\n<p>In February, Reckitt sold its Scholl footcare business to private equity firm Yellow Wood Partners, and a few months later signed a deal to sell its infant formula business in China for $2.2 billion to Primavera Capital Group.</p>\n<p>Reuters had reported last year that the company was preparing to sell some non-core brands and was seeking out private equity bidders.</p>\n<p>\"As we shift from a brand-led to a category-led growth strategy, we are focusing on high growth categories with brands we can stretch into new places and spaces to support our medium-term growth ambitions, including 4%-6% growth in Health (business),\" CEO Laxman Narasimhan said in a statement.</p>\n<p>In a separate statement, Karo Pharma said the deal is structured as a put option agreement and when completed will scale up its operations in the United Kingdom and strengthen its position in the dermatology category.</p>\n<p>Reckitt will provide service and manufacturing support to Karo for a limited time following completion of the deal, which is expected in the second quarter of 2022, Karo Pharma said in a statement.</p>\n<p>No manufacturing sites are included as part of the deal and Karo intends to transfer production to a new third party contract manufacturing organization, the Stockholm-based healthcare company added.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reckitt to sell E45 skincare brand to Karo Pharma for $268 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReckitt to sell E45 skincare brand to Karo Pharma for $268 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -Reckitt Benckiser said on Friday it plans to sell its E45 skincare brand and related sub-brands to Karo Pharma for 200 million pounds ($267.98 million), as the British consumer goods maker shifts focus to higher growth areas.</p>\n<p>The Durex condom and Lysol disinfectant maker said the businesses generated a combined net revenue of 43 million pounds last year.</p>\n<p>The Slough-based company has been trimming its portfolio to concentrate on high growth categories such as disinfectants and health care products that have seen a boom during the COVID-19 pandemic.</p>\n<p>In February, Reckitt sold its Scholl footcare business to private equity firm Yellow Wood Partners, and a few months later signed a deal to sell its infant formula business in China for $2.2 billion to Primavera Capital Group.</p>\n<p>Reuters had reported last year that the company was preparing to sell some non-core brands and was seeking out private equity bidders.</p>\n<p>\"As we shift from a brand-led to a category-led growth strategy, we are focusing on high growth categories with brands we can stretch into new places and spaces to support our medium-term growth ambitions, including 4%-6% growth in Health (business),\" CEO Laxman Narasimhan said in a statement.</p>\n<p>In a separate statement, Karo Pharma said the deal is structured as a put option agreement and when completed will scale up its operations in the United Kingdom and strengthen its position in the dermatology category.</p>\n<p>Reckitt will provide service and manufacturing support to Karo for a limited time following completion of the deal, which is expected in the second quarter of 2022, Karo Pharma said in a statement.</p>\n<p>No manufacturing sites are included as part of the deal and Karo intends to transfer production to a new third party contract manufacturing organization, the Stockholm-based healthcare company added.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBGLY":"Reckitt Benckiser Group Plc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166205101","content_text":"(Reuters) -Reckitt Benckiser said on Friday it plans to sell its E45 skincare brand and related sub-brands to Karo Pharma for 200 million pounds ($267.98 million), as the British consumer goods maker shifts focus to higher growth areas.\nThe Durex condom and Lysol disinfectant maker said the businesses generated a combined net revenue of 43 million pounds last year.\nThe Slough-based company has been trimming its portfolio to concentrate on high growth categories such as disinfectants and health care products that have seen a boom during the COVID-19 pandemic.\nIn February, Reckitt sold its Scholl footcare business to private equity firm Yellow Wood Partners, and a few months later signed a deal to sell its infant formula business in China for $2.2 billion to Primavera Capital Group.\nReuters had reported last year that the company was preparing to sell some non-core brands and was seeking out private equity bidders.\n\"As we shift from a brand-led to a category-led growth strategy, we are focusing on high growth categories with brands we can stretch into new places and spaces to support our medium-term growth ambitions, including 4%-6% growth in Health (business),\" CEO Laxman Narasimhan said in a statement.\nIn a separate statement, Karo Pharma said the deal is structured as a put option agreement and when completed will scale up its operations in the United Kingdom and strengthen its position in the dermatology category.\nReckitt will provide service and manufacturing support to Karo for a limited time following completion of the deal, which is expected in the second quarter of 2022, Karo Pharma said in a statement.\nNo manufacturing sites are included as part of the deal and Karo intends to transfer production to a new third party contract manufacturing organization, the Stockholm-based healthcare company added.","news_type":1},"isVote":1,"tweetType":1,"viewCount":608,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":71,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}